The safety of ORLADEYO® (berotralstat) is supported
by data from patients across 2 clinical studies1

In APeX-2 (part 1), the most commona treatment-emergent adverse reactions were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease (GERD)1

ORLADEYO™ APeX-2 study adverse reaction summary ORLADEYO™ APeX-2 study adverse reaction summary

a≥10% and higher than placebo.1
bIncludes abdominal pain, abdominal discomfort, abdominal tenderness, and upper abdominal pain.1
cIncludes diarrhea and frequent bowel movements.1

Gastrointestinal (GI) adverse reactions generally occurred early after initiation of treatment,
became less frequent with time, and typically self-resolved1

Most commond adverse reactions in APeX-2 parts 1 and 2 or part 33

One patient receiving ORLADEYO 150 mg discontinued treatment due to GI abdominal adverse reactions in APeX-2 part 33

d>10% of patients for APeX-2 part 1 and 2 or part 3.3
eFrom an ad hoc, interim analysis of 26 patients who finished 48 weeks of treatment and entered APeX-2 part 3.3

Findings from the open-label, long-term safety study, APeX-S (interim
safety population, n=227), support the data observed in APeX-2 (part 1).1,4